Published in Antimicrob Agents Chemother on February 01, 1975
Susceptibility of anaerobic bacteria to 23 antimicrobial agents. Antimicrob Agents Chemother (1976) 9.53
In vitro activity of thienamycin. Antimicrob Agents Chemother (1978) 8.76
In vitro activity of LY127935. Antimicrob Agents Chemother (1979) 7.01
Cloning and sequencing of the class B beta-lactamase gene (ccrA) from Bacteroides fragilis TAL3636. Antimicrob Agents Chemother (1990) 5.24
Cefoxitin resistance to beta-lactamase: a major factor for susceptibility of bacteroides fragilis to the antibiotic. Antimicrob Agents Chemother (1977) 4.14
Activity of cefamandole and other cephalosporins against aerobic and anaerobic bacteria. Antimicrob Agents Chemother (1976) 4.07
Beta-lactamase-mediated imipenem resistance in Bacteroides fragilis. Antimicrob Agents Chemother (1986) 3.87
Beta-lactamase activity in anaerobic bacteria. Antimicrob Agents Chemother (1976) 2.75
Comparative in vitro activity of new beta-lactam antibiotics against anaerobic bacteria. Antimicrob Agents Chemother (1981) 2.71
Antimicrobial susceptibilities of 1,292 isolates of the Bacteroides fragilis group in the United States: comparison of 1981 with 1982. Antimicrob Agents Chemother (1984) 2.71
In vitro activity of azthreonam, a monobactam antibiotic. Antimicrob Agents Chemother (1982) 2.70
Comparative study of the in vitro antibacterial activity of cefoxitin, cefuroxine, and cephaloridine. Antimicrob Agents Chemother (1976) 2.65
Cefoxitin inactivation by Bacteroides fragilis. Antimicrob Agents Chemother (1983) 2.64
Nationwide study of the susceptibility of the Bacteroides fragilis group in the United States. Antimicrob Agents Chemother (1985) 2.47
Susceptibility of the Bacteroides fragilis group in the United States: analysis by site of isolation. Antimicrob Agents Chemother (1988) 2.45
Rapid microbiological assay for chloramphenicol and tetracyclines. Antimicrob Agents Chemother (1976) 2.26
Cefuroxime, a new parenteral cephalosporin: collaborative in vitro susceptibility comparison with cephalothin against 5,887 clinical bacterial isolates. Antimicrob Agents Chemother (1977) 2.04
In vitro evaluation of cefoxitin and cefamandole. Antimicrob Agents Chemother (1976) 1.78
Comparative in vitro activity of newer cephalosporins against anaerobic bacteria. Antimicrob Agents Chemother (1978) 1.72
Comparative susceptibility of anaerobic bacteria to ticarcillin, cefoxitin, metronidazole, and related antimicrobial agents. Antimicrob Agents Chemother (1977) 1.67
Susceptibility of anaerobic bacteria to nine antimicrobial agents and demonstration of decreased susceptibility of Clostridium perfringens to penicillin. Antimicrob Agents Chemother (1981) 1.63
Cefoxitin: clinical evaluation in thirty-eight patients. Antimicrob Agents Chemother (1977) 1.58
In vitro of cefotaxime against cephalothin-resistant clinical isolates. Antimicrob Agents Chemother (1979) 1.48
Comparative in vitro activities of cefpiramide and apalcillin against anaerobic bacteria. Antimicrob Agents Chemother (1984) 1.43
Susceptibility of Propionibacterium acnes to seventeen antibiotics. Antimicrob Agents Chemother (1977) 1.42
Multicenter study of in vitro susceptibility of the Bacteroides fragilis group, 1995 to 1996, with comparison of resistance trends from 1990 to 1996. Antimicrob Agents Chemother (1999) 1.38
Antimicrobial spectrum of Win 49375. Antimicrob Agents Chemother (1984) 1.31
Susceptibility of Clostridium botulinum to thirteen antimicrobial agents. Antimicrob Agents Chemother (1980) 1.26
Transfer of beta-lactamase-associated cefoxitin resistance in Bacteroides fragilis. Antimicrob Agents Chemother (1986) 1.24
Antimicrobial activity of metronidazole in anaerobic bacteria. Antimicrob Agents Chemother (1978) 1.23
Susceptibility of respiratory tract anaerobes to orally administered penicillins and cephalosporins. Antimicrob Agents Chemother (1976) 1.23
Contribution of enzymatic properties, cell permeability, and enzyme expression to microbiological activities of beta-lactams in three Bacteroides fragilis isolates that harbor a metallo-beta-lactamase gene. Antimicrob Agents Chemother (1994) 1.17
Subgaleal abscess: a preventable complication of scalp trauma. West J Med (1977) 1.17
Activity of newer beta-lactam agents against clinical isolates of Bacteroides fragilis and other Bacteroides species. Antimicrob Agents Chemother (1987) 1.16
Use of cefoxitin, new cephalosporin-like antibiotic, in the treatment of aerobic and anaerobic infections. Antimicrob Agents Chemother (1978) 1.10
Comparative activities of newer beta-lactam agents against members of the Bacteroides fragilis group. Antimicrob Agents Chemother (1990) 1.04
Activity of trospectomycin against Bacteroides fragilis and other Bacteroides species. Antimicrob Agents Chemother (1988) 1.02
Susceptibility of anaerobic bacteria to cofoxitin and related compounds. Antimicrob Agents Chemother (1977) 1.01
Failure of single doses of cefazolin and cefamandole to penetrate experimental chronic Escherichia coli abdominal abscesses. Antimicrob Agents Chemother (1980) 0.99
Pharmacokinetic and clinical studies on cefuroxime. Proc R Soc Med (1977) 0.98
Antimicrobial susceptibilities of anaerobic bacteria isolated from female genital tract infections. Antimicrob Agents Chemother (1985) 0.96
Bacteroides fragilis resistance to clindamycin in vitro. Antimicrob Agents Chemother (1982) 0.96
Prospective comparison of cefoxitin and cefazolin in infections caused by aerobic bacteria. Antimicrob Agents Chemother (1978) 0.93
Comparison of kill-kinetic studies with agar and broth microdilution methods for determination of antimicrobial activity of selected agents against members of the Bacteroides fragilis group. J Clin Microbiol (1987) 0.92
Susceptibility to five antimicrobial agents of strains of the Bacteroides fragilis group isolated in Brazil. Antimicrob Agents Chemother (1987) 0.89
Activity of cefmetazole against anaerobic bacteria. Antimicrob Agents Chemother (1987) 0.89
In vitro activity of cefbuperazone against Bacteroides spp. Antimicrob Agents Chemother (1985) 0.85
Factors affecting the in vitro activity of cefoperazone against the Bacteroides fragilis group. Antimicrob Agents Chemother (1981) 0.83
In vitro activity of Sch 34343 and cefbuperazone against anaerobic bacteria. Antimicrob Agents Chemother (1985) 0.81
The third generation cephalosporins. Bull N Y Acad Med (1982) 0.76
Clinical experience in the treatment of pneumonia with cefuroxime. Proc R Soc Med (1977) 0.75
Comparative in vitro activity of cefbuperazone against anaerobic bacteria isolated from community hospitals. Antimicrob Agents Chemother (1985) 0.75
[In vitro testing of newer cephalosporins (author's transl)]. Infection (1979) 0.75
Antibiotic sensitivity testing. Report of an international collaborative study. Acta Pathol Microbiol Scand B Microbiol Immunol (1971) 40.37
In vitro antimicrobial susceptibility of anaerobic bacteria isolated from clinical specimens. Antimicrob Agents Chemother (1972) 11.05
Cefoxitin, a semisynthetic cephamycin antibiotic: resistance to beta-lactamase inactivation. Antimicrob Agents Chemother (1974) 8.84
Anaerobic infections. 1. N Engl J Med (1974) 8.02
Cefoxitin, a semisynthetic cephamycin antibiotic: susceptibility studies. Antimicrob Agents Chemother (1974) 6.72
The susceptibility of Bacteroides fragilis to 24 antibiotics. J Infect Dis (1972) 6.12
Characterisation of a -lactamase obtained from a strain of Bacteroides fragilis resistant to -lactam antibiotics. J Med Microbiol (1973) 4.58
Cephamycins, a new family of beta-lactam antibiotics: antibacterial activity and resistance to beta-lactamase degradation. Antimicrob Agents Chemother (1973) 4.45
Cephalosporinase activity in Bacteroides fragilis. Antimicrob Agents Chemother (1973) 3.27
Abdominal trauma, anaerobes, and antibiotics. Surg Gynecol Obstet (1973) 3.18
Blood, urine and tissue concentrations of the cephalosporin antibiotics in normal subjects. Postgrad Med J (1971) 2.79
Cefoxitin, a new semi-synthetic cephamycin: an in-vitro and in-vivo comparison with cephalothin. Br Med J (1973) 2.23
Comparative serum levels and urinary recovery of cefazolin, cephaloridine, and cephalothin in man. J Clin Pharmacol (1974) 1.74
Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med (1978) 14.65
Plasmid-controlled colonization factor associated with virulence in Esherichia coli enterotoxigenic for humans. Infect Immun (1975) 14.65
Tularemia as a biological weapon: medical and public health management. JAMA (2001) 13.23
Production of vascular permeability factor by enterotoxigenic Escherichia coli isolated from man. Infect Immun (1973) 9.99
Botulinum toxin as a biological weapon: medical and public health management. JAMA (2001) 9.18
In vitro activity of thienamycin. Antimicrob Agents Chemother (1978) 8.76
Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA (2000) 8.45
Anaerobic infections. 1. N Engl J Med (1974) 8.02
Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA (1999) 7.96
Clindamycin-associated colitis due to a toxin-producing species of Clostridium in hamsters. J Infect Dis (1977) 7.68
Enterotoxigenic Escherichia coli isolated from patients with severe cholera-like disease. J Infect Dis (1971) 7.10
Anthrax as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA (1999) 7.06
In vitro activity of LY127935. Antimicrob Agents Chemother (1979) 7.01
Acute undifferentiated human diarrhea in the tropics. I. Alterations in intestinal micrflora. J Clin Invest (1971) 6.23
Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis. Gastroenterology (1978) 5.91
Toxigenic Escherichia coli: a cause of infantile diarrhea in Chicago. N Engl J Med (1972) 5.45
Cloning and sequencing of the class B beta-lactamase gene (ccrA) from Bacteroides fragilis TAL3636. Antimicrob Agents Chemother (1990) 5.24
Treating diarrhoea. BMJ (1997) 5.22
Travelers' diarrhea and toxigenic Escherichia coli. N Engl J Med (1975) 5.20
Comparison of two toxins produced by Clostridium difficile. Infect Immun (1981) 5.16
Polymyxin B-Induced Release of Low-Molecular-Weight, Heat-Labile Enterotoxin from Escherichia coli. Infect Immun (1974) 4.79
Glanders in a military research microbiologist. N Engl J Med (2001) 4.77
In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother (1999) 4.44
Clostridium difficile colitis: an efficient clinical approach to diagnosis. Ann Intern Med (1995) 4.42
Cytotoxicity assay in antibiotic-associated colitis. J Infect Dis (1979) 4.39
Activity of cefamandole and other cephalosporins against aerobic and anaerobic bacteria. Antimicrob Agents Chemother (1976) 4.07
Identification of enterotoxigenic Escherichia coli and serum antitoxin activity by the vascular permeability factor assay. Infect Immun (1973) 4.07
Isolation rates and toxigenic potential of Clostridium difficile isolates from various patient populations. Gastroenterology (1981) 4.04
Clindamycin-induced enterocolitis in hamsters as a model of pseudomembranous colitis in patients. Infect Immun (1978) 3.93
Experimental intra-abdominal abscesses in rats: development of an experimental model. Infect Immun (1974) 3.91
In vitro activity of N-formimidoyl thienamycin (MK0787). Antimicrob Agents Chemother (1980) 3.90
Clinical and laboratory observations in Clostridium difficile colitis. Am J Clin Nutr (1980) 3.89
Beta-lactamase-mediated imipenem resistance in Bacteroides fragilis. Antimicrob Agents Chemother (1986) 3.87
Intestinal microflora. Gastroenterology (1971) 3.86
Intestinal flora in health and disease. Gastroenterology (1984) 3.84
Susceptibility of the Bacteroides fragilis group in the United States in 1981. Antimicrob Agents Chemother (1983) 3.83
Quantitative bacteriology of the vaginal flora. J Infect Dis (1977) 3.81
Principles of appropriate antibiotic use for acute pharyngitis in adults: background. Ann Intern Med (2001) 3.75
Studies of intestinal microflora. II. Microorganisms of the small intestine and their relations to oral and fecal flora. Gastroenterology (1967) 3.71
Management of anaerobic infections. Ann Intern Med (1975) 3.62
Metronidazole versus anaerobes. In vitro data and initial clinical observations. Calif Med (1972) 3.62
The capsular polysaccharide of Bacteroides fragilis as a virulence factor: comparison of the pathogenic potential of encapsulated and unencapsulated strains. J Infect Dis (1977) 3.62
Studies of intestinal microflora. I. Effects of diet, age, and periodic sampling on numbers of fecal microorganisms in man. Gastroenterology (1967) 3.60
Rapid diagnosis of anaerobic infections by direct gas-liquid chromatography of clinical speciments. J Clin Invest (1976) 3.34
Anaerobic pleuropulmonary infections. Medicine (Baltimore) (1972) 3.30
Microbial synergy in experimental intra-abdominal abscess. Infect Immun (1976) 3.21
Abdominal trauma, anaerobes, and antibiotics. Surg Gynecol Obstet (1973) 3.18
Anaerobic infections (second of three parts). N Engl J Med (1974) 3.18
Principles of appropriate antibiotic use for acute rhinosinusitis in adults: background. Ann Intern Med (2001) 3.15
Colitis induced by Clostridium difficile. Rev Infect Dis (1980) 3.15
Anaerobic infections (third of three parts). N Engl J Med (1974) 3.13
Bacteroides fragilis resistant to the administration of clindamycin. Am J Med (1976) 3.13
In vitro and in vivo antibacterial activities of the glycylcyclines, a new class of semisynthetic tetracyclines. Antimicrob Agents Chemother (1993) 3.13
Intestinal fluid and electrolyte transport in human cholera. J Clin Invest (1970) 3.09
Enzyme immunoassays for detection of Clostridium difficile toxins A and B in fecal specimens. J Infect Dis (1984) 3.07
Treatment of anaerobic infections with lincomycin and clindamycin. N Engl J Med (1972) 3.05
Studies on enterotoxin from Escherichia coli associated with acute diarrhea in man. J Lab Clin Med (1971) 3.03
Antibiotic-associated pseudomembranous colitis. Rev Infect Dis (1980) 3.02
Oral vancomycin for antibiotic-associated pseudomembranous colitis. Lancet (1978) 2.87
Cultures for Clostridium difficile in stools containing a cytotoxin neutralized by Clostridium sordellii antitoxin. J Clin Microbiol (1979) 2.86
Characterization of pBFTM10, a clindamycin-erythromycin resistance transfer factor from Bacteroides fragilis. J Bacteriol (1982) 2.80
Survival of Lactobacillus species (strain GG) in human gastrointestinal tract. Dig Dis Sci (1992) 2.78
Oxygen tolerance of fresh clinical anaerobic bacteria. J Clin Microbiol (1975) 2.77
Inactivation of cephalosporins by Bacteroides. Antimicrob Agents Chemother (1979) 2.75
Pseudomembranous enterocolitis (antibiotic-related colitis). Adv Intern Med (1977) 2.73
Antimicrobial susceptibilities of 1,292 isolates of the Bacteroides fragilis group in the United States: comparison of 1981 with 1982. Antimicrob Agents Chemother (1984) 2.71
In vitro activity of azthreonam, a monobactam antibiotic. Antimicrob Agents Chemother (1982) 2.70
Cefoxitin inactivation by Bacteroides fragilis. Antimicrob Agents Chemother (1983) 2.64
Symptomatic relapse after oral vancomycin therapy of antibiotic-associated pseudomembranous colitis. Gastroenterology (1980) 2.60
Hormone levels during dietary changes in premenopausal African-American women. J Natl Cancer Inst (1996) 2.59
Effect of preoperative neomycin-erythromycin intestinal preparation on the incidence of infectious complications following colon surgery. Ann Surg (1973) 2.57
Antimicrobial therapy of experimental intraabdominal sepsis. J Infect Dis (1975) 2.56
Stimulation of intestinal adenyl cyclase by Escherichia coli enterotoxin: comparison of strains from an infant and an adult with diarrhea. J Infect Dis (1974) 2.52
Tn4400, a compound transposon isolated from Bacteroides fragilis, functions in Escherichia coli. J Bacteriol (1985) 2.48